

# Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

10/5/2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present and host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit taking place October 11 – 12, 2023 in New York City, New York.

## Jefferies Inaugural Biotech CNS/Neuro Summit Details

Fireside Chat Date and Time: Thursday, October 12, 2023 at 12:00 p.m. Pacific Time

Location: Jefferies Conference Center in New York City, New York

A webcast will be accessible through the Events page in the Investors section of the Company's website at **[www.Vistagen.com](http://www.Vistagen.com)**. Investors interested in arranging a one-on-one meeting during the conference should contact their Jefferies representative.

## About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug of an antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines are neuroactive nasal

sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression, and several other CNS disorders. Connect at [www.Vistagen.com](http://www.Vistagen.com).

Investors:

Mark McPartland

Senior Vice President, Investor Relations

(650) 577-3606

**[markmcp@vistagen.com](mailto:markmcp@vistagen.com)**

Media:

Nate Hitchings

SKDK

**[nhitchings@skdknick.com](mailto:nhitchings@skdknick.com)**

Source: Vistagen